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Abstract
Background: The use of an overall risk assessment based on genomic information is consistent with precision medicine.
Despite the enthusiasm, there is a need for public engagement on the appropriate use of such emerging technologies in
order to frame meaningful evaluations of utility, including the practical implementation and acceptability issues that
might emerge. Doing so requires the involvement of the end users of these services, including patients, and sections of
the public who are the target group for population based screening. In the present study we sought to explore public
attitudes to the potential integration of personal genomic profiling within existing population screening programs; and to
explore the evolution of these attitudes as part of a deliberative process.
Methods: We conducted a mixed methods study presented in the format of a deliberative workshop. Participants
were drawn from communities in Ottawa, Ontario (ON) and St John’s, Newfoundland and Labrador (NL), Canada.
Individuals were approached to take part in a workshop on the incorporation of genomic risk profiling for either
colorectal cancer screening (CRC), or newborn screening for type 1 diabetes mellitus (T1DM).
Results: A total of N = 148 (N = 65 ON, N = 83 NL) participants provided data for analysis. Participants in both
groups were supportive of public funding for genomic risk profiling, although participants in the T1DM groups
expressed more guarded positive attitudes than participants in the CRC groups. These views were stable throughout
the workshop (CRC, p = 0.15, T1DM, p =0.39). Participants were less positive about individual testing, with a significant
decrease in support over the course of the workshop (CRC p = 0.02, T1DM, p = 0.003). Common concerns related to
access to test results by third parties.
Conclusions: The findings of this study suggest that members of the target populations for potential genomic profiling
tests (designed for screening or risk prediction purposes) can engage in meaningful deliberation about their general
acceptability and personal utility. Evaluations of whether a test would be personally useful may depend on the
experience of the participants in personal health decision making, the purpose of the test, and the availability of
interventions to reduce disease risk.
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Background
Rapid advances in technology since the completion of the
Human Genome Project have led to significantly decreased
costs and timeframes for integrating genomic information
into routine health care [1]. While much attention has
been given to the potential of whole genome or exome
sequencing, considerable efforts have also been directed
towards more targeted approaches. One of these is gen-
omic profiling, in which multiple common genomic sus-
ceptibility variants are combined to offer risk stratification
for a target disease [2]. Genomic profiling is distinguished
from genetic testing by its focus on normal variation, mod-
est risk alterations, and an integrated approach, rather than
on detecting specific, rare disease-associated, high pene-
trance alleles [3]. In particular it involves examining the
genome for single nucleotide polymorphisms (SNPs) [3],
the most common type of genetic variation related to com-
mon disease [4, 5]. While each variant may be only weakly
associated with pathology, it has been proposed that a
combination of variants may collectively explain a portion
of the risk of a given disease [6].
While the predictive ability of such assessments may be
limited when applied to individuals, and will vary between
conditions due to the genetic complexity of the disease in
question and influence of the environment on gene ex-
pression [7, 8], incorporating genomic profiling data in
population based screening programs – in addition to risk
based primarily on age, for example – could reduce false
positive or negative results, and over-diagnosis [2, 9]. If
successful, this would reduce harms such as anxiety and
unnecessary diagnostic tests, and improve the use of
scarce health care resources.
While there is much expressed enthusiasm about the
idea of personalized medicine and ‘personal genomics’,
there is a need for public engagement on the appropri-
ate use of such emerging technologies in reality. We
need to know more about how they might play out in
practice in order to frame meaningful evaluations of
utility, including the practical implementation and ac-
ceptability issues that might emerge. For example, to
what extent do traditional principles of screening such
as actionability of results weigh into participants’ evalu-
ations and intentions [9] compared with emergent is-
sues such as ‘personal utility’ [9–11] or characteristics
of the test or disease in question [12, 13]? These ques-
tions require the involvement of those who are the end
users of these services, including patients, and sections
of the public who are the target group for population
based screening.
Engaging with the public about genomics
The engagement of publics in policy discussions about
topics such as genomics and healthcare can be justified
on a number of grounds. Firstly, legitimacy and fairness
demand that in a healthcare system that is publicly
funded, the public be involved in decisions regarding
how those funds are used. Greater involvement of the
public is also in keeping with democratic principles [14],
may provide greater support for the decisions made (as-
suming they are compatible with the expressed views),
and could potentially lead to increased trust in decision-
makers and the decision-making process.
Beyond the potential impact on individuals’ anxiety or
motivation, augmenting risk information through gen-
omic profiling might eventually change implicit frame-
works of understanding about disease causation [15], the
perceived role of prevention and lifestyle [16, 17], and
the sense of personal responsibility for one’s own health
[18, 19]. Concerns have also been raised about the privacy
of personal genomic information, and that genomic risk
information could be used in the calculation of, or eligi-
bility for, individual insurance premiums or employers’
screening requirements [20–22]. While the Genetic Infor-
mation Nondiscrimination Act (GINA) was signed into
US law in 2008 [23], no such legislation exists in Canada,
although this has been the subject of recent debate [24].
Finally, and to reiterate, the incorporation of public
attitudes is a necessary component of implementation
research: how members of target user groups view and
respond to genomic information will influence accept-
ability and demand, and therefore set the upper limit on
the overall beneficial impact that an effective technology
will achieve in practice [1].
The effect of deliberation on attitudes
The analysis of public attitudes is a developing area
within the field of research focused on the integration of
genomics into healthcare. A range of methods have been
incorporated into existing studies, from traditional quali-
tative techniques such as focus groups, to quantitative
approaches such as structured surveys [25–30]. More
recently, approaches that seek to promote discussion
and deliberation have been advocated, with the goal of
obtaining more informed views and understanding of
the issues at hand [31–35]. Such deliberative approaches
tend to be characterized by their structure, often involv-
ing the provision of background information about the
issue under discussion and relevant technical details, as
well as their relatively small size and discursive format
[31]. Implicit within this is the assumption that opinions
will crystallize or even change as a result of the delibera-
tive process [31, 36].
While we have previously explored the qualitative
arguments provided by participants for their support for,
or concerns regarding, the implementation of genomic
risk profiles as part of population screening [37], there
is a lack of data regarding the role that deliberation has
on the formation of these attitudes. A recent review of
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public attitudes to genetics called “for more detailed re-
search in particular aspects of attitudes about genetics
in order to understand how these attitudes operate in
behavior or policy preferences” [28], and some have
called for research that investigates how much specific
deliberative elements contribute to the outcomes of
such exercises, given that there has been little research
in this area [38].
The primary aim of this study was to examine the atti-
tudes of specific population target groups to the poten-
tial integration of hypothetical genomic profiling, using
their experiences with existing screening programs as a
starting point for deliberation. Secondary aims were to
compare how the two groups responded, given the two
different screening contexts, and to assess how much at-
titudes shifted during the deliberative process. As such,
the study builds on previous research regarding public
attitudes toward genomics to explore the influence of
deliberative processes on attitudes and attempts to
quantitatively evaluate the impact of context and process
on the development of these attitudes.
Methods
We conducted an exploratory, mixed methods study in
which attitudes to hypothetical uses of genomic profiling
were explored in semi-structured workshops. (Further de-
tails provided below.) We noted from previous studies that
specific discussions of technologies may elicit attitude vari-
ations better than more abstract approaches. We therefore
developed workshops on two topics to which we judged
participants would be able to relate, and then recruited
participants with demographic attributes to fit these no-
tional screening approaches. We captured data in three
ways: contemporaneous written comments by participants,
structured survey items, and non-participant observation.
Details of the study have been described previously [37];
we focus here on detailing the structured data collection
and analysis.
Topic selection
The two workshop topics were genomic profiling for
colorectal cancer (CRC) risk assessment in adults, and
for type 1 diabetes (T1DM) risk assessment in infants.
CRC is a leading cause of mortality in North America
[38, 39], with an inherited component to its incidence
[40, 41]. Evidence supports the potential for genomic
profiling based on multiple common variants as an ap-
proach to risk stratification, and possibly incorporation
into population screening [6, 40, 42]. T1DM is a chronic
disease most often diagnosed in childhood [43, 44], and
is apparently increasing in incidence [45]. The potential
suitability of including T1DM in existing newborn
screening (NBS) panels has been discussed [46, 47].
Deliberative workshop format
The deliberative workshop approach was informed by
previous public engagement studies examining socio-
ethical issues in genomics [48–50]. A summary of the
approach is presented in Fig. 1. Briefly, each workshop
comprised three rounds, each of which itself contained
three components: a standardized information set relat-
ing to the hypothetical genomic risk profiling test under
discussion, a deliberative period for plenary discussion,
and brief structured collection of attitude data.
The details of the information sets are provided in
Table 1 (see also Additional file 1). They were developed
by a multidisciplinary group which included clinical ex-
perts, health psychologists, and epidemiologists. The set
for each workshop comprised three parts, with the con-
tent moving from (a) basic orientation to the clinical
context, including the rationale for the use of genomic
test, to (b) consideration of potential individual bene-
fits, harms, and consequences, to (c) consideration of
wider issues including ethical and social issues. They
therefore included background information on current
(non-genomic) screening approaches, potential advan-
tages and disadvantages of a genomic profiling ap-
proach, and potential impacts for themselves and
family members. We emphasized that the tests were
not yet available, and that their purpose was to inform
risk assessment, but they were not themselves screening
tests. In the absence of actual data on the validity or
utility of these hypothetical tests, we extrapolated from
evidence in the wider genetics literature. The informa-
tion was worded neutrally and attempted to communi-
cate a balanced approach to the potential merits or
otherwise of the genomic tests. For the phrase “genomic
profiling”, we substituted the term “DNA based risk test”,
for two reasons: first, because the phrase “genomic profil-
ing” is used in other contexts which might prove confusing
to some participants (e.g., genomic profiling of tumours
was not within the scope of this study), but we wished to
retain a clear link to the idea of genetics or genomics; and
second, because we wished to reinforce as much as pos-
sible the idea of linking the test with personal health risk in
some way.
We used PowerPoint to present the information sets,
and allowed questions for clarification. Deliberative com-
ponents were discursive with the aim of discussing and
debating the issues brought up by the information sets
rather than a priori discussion questions. Participants
were, however, not limited to discussing only the content
of the information sets, allowing them to draw on previ-
ous topics or to raise new issues. The deliberative stages
were facilitated by a member of the research team who
also served as presenter for the information sets. The
workshop finished with concluding structured attitude
questions and collection of demographic data.
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Participants and recruitment
Participants were recruited from community based groups
in Ottawa, Ontario (ON), and St John’s, Newfoundland
and Labrador (NL), Canada. Participants were invited to
take part in a workshop matched to their demographic
characteristics.
Individuals were eligible for the CRC workshop if they
were aged 50 years or older, consistent with eligibility cri-
teria for provincial screening programs. Individuals were
eligible for participation in the T1DM workshop if they
had fairly recent experience of being offered NBS (defined
in practice as a having child under five years of age).
Hence, participants in the CRC workshops targeted older
individuals, and the T1DM groups were younger.
In Ottawa, we recruited participants directly through
community-based groups, such as seniors’ centres and
groups for new parents. In St. John’s, individuals were
recruited using random digit dialing. Irrespective of re-
cruitment approach, participants were informed about
the study and if they indicated interest they were pro-
vided written information and a consent form. On the
day of the workshop participants were reminded of the
study objectives and requirements and completed a con-
sent form.
The protocol was approved by the Ottawa Hospital Re-
search Ethics Board and the Newfoundland and Labrador
Health Research Ethics Authority.
Analytical strategy and data collection
As a mixed methods study, the three types of data col-
lection were designed to be complementary and mutu-
ally informative. We report here the analysis of the
structured data, reviewed in isolation from the other
data sets. At the outset, it is important to note that, be-
cause the overall approach was qualitative, these analyses
cannot be considered hypothesis testing, and the data
themselves do not meet criteria for an epidemiological
approach.
For the present analysis we focus principally on responses
to the two “tracker” attitude questions that were repeated
after each information set and discussion. We captured
these responses repeatedly in order to assess how responses
changed over the course of the workshop.
The first tracker question was designed to capture atti-
tudes towards the general acceptability of the hypothet-
ical test, and was worded:
“If DNA risk tests for colon cancer/type 1 diabetes
became available, do you think [Province] should pay
for them?”
The second tracker question was designed to capture
the more personal assessment of the utility of the hypo-
thetical test, and was worded:
“When you think about your own/your child’s
situation, would you want/want him or her to have a
DNA risk test for colon cancer/type 1 diabetes?”
Fig. 1 Schematic of the workshop format
Table 1 Key elements of information sets
Information Set 1. The idea of genomic profiling
• Description of colorectal cancer/newborn bloodspot screening program
• Genomic profiling test (referred to as ‘DNA risk test’) and how this
could be used implemented
• Emphasis on the technology and improvement on current
approaches, and potential benefits e.g. reducing unnecessary
interventions and targeting interventions to those most at risk
Information Set 2. The potential personal impacts of having a test
• Potential advantages: lifestyle choices, screening participation,
attending promptly to early symptoms; personal utility of
knowledge irrespective of potential for risk reduction
• Potential disadvantages: anxiety, depression, disease worry, reduced
quality of life (if higher risk); failure to follow health advice, neglect
of early symptoms (if lower risk)
• Potential for effects on others: e.g. family members, as well access
and use by third parties (e.g. insurance companies)
• Idea that results are not transient but ‘for life’
Information Set 3. Reiteration of the nature of such a test, and its place
in personal health management
• Integration of genomic profiling within broader set of risk
assessment and screening tests
• Reinforcement of risk not actual disease status conferred by the tests
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For both questions, responses were coded on a 5-point
Likert scale ranging from Definitely Yes to Definitely No.
We also present analyses of nine attitude questions in-
cluded in the concluding survey (See Results and Table 2
for details). The items were developed to capture attitudes
to issues framed at both policy/societal level (e.g. “I think
that DNA risk tests for colon cancer are generally accept-
able”), and personal level (e.g. “I would ask my doctor for
this test”). Responses were scored as either Yes/No or on a
5 point Likert scale from Strongly Agree to Strongly Dis-
agree. General feelings about the technology were captured
by asking participants to select from a list of positive, nega-
tive and neutral “valence words” [51]. Standard demo-
graphic information was also collected.
Analysis
All responses were collated and imported into IBM SPSS
Statistics v22 [52] for analysis. Due to the relatively small
sample sizes, purposive sampling, and exploratory nature
of the study, extensive statistical analyses were inappro-
priate, and we took a largely descriptive approach. How-
ever, to assist interpretation of the comparisons within
Table 2 Demographic information of participants completing the survey measures
CRC (N = 108) n (%) T1DM (N = 40) n (%) Fisher’s Exact test (2 sided)
Sex P = 0.26
Female: 55 (23) 29 (73)
Male 25 (51) 7 (17)
Missing 28 (26) 4 (10)
Marital Status P < 0.01
Married or living with partner: 51 (47) 35 (87.5)
Widowed 15 (14) 0
Divorced or separated 10 (9) 0
Single, never married 4 (4) 1 (2.5)
Missing 28 (26) 4 (10)
Highest level of educational attainment P = 0.02
University degree - graduate or higher: 17 (16) 13 (33)
University degree - undergraduate 15 (14) 9 (22.5)
Community college, technical college, or CEGEP 23 (21) 8 (20)
Secondary 15 (14) 1 (2)
Professional degree 4 (4) 5 (12.5)
Other training or education 6 (6) 0
Missing 28 (26) 4 (10)
Average income P < 0.01
$0–29,999 13 (12) 1 (2.5)
$30,000–49,999 17 (16) 1 (2.5)
$50,000–69,999 18 (17) 6 (15)
$70,000+ 25 (23) 26 (65)
Missing 35 (32) 6 (15)
Ethnicity P = 1.0
White 77 (71) 35 (87.5)
Native Canadian 2 (2) 0
Missing 29 (27) 5 (12.5)
Language spoken at home P = 0.38
English 73 (68) 35 (87.5)
French 2 (2) 0
Both English and French 5 (5) 0
Missing 28 (26) 5 (12.5)
T1DM Type 1 Diabetes Mellitus, CRC Colorectal Cancer, CEGEP Collège d’enseignement général et professionnel
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the workshop groups, and between the two topics, we
selectively examined statistical significance with non-
parametric tests.
For the tracker questions, we used the Friedman test,
because of the skewness of the data. The Wilcoxon sign
rank test was used to compare pairs of rounds, and The
Mann Whitney U Test for comparisons of change in
attitudes across groups. Responses to general attitude
questions were compared using the χ2 statistic. For all
statistical tests, a level of p <0.05 was accepted as
significant.
Results
Workshops were conducted between November 2011
and July 2012. A total of 200 participants attended the
workshops (65 in ON, 135 in NL). Because of a technical
problem, linked data for 52 NL participants are unavail-
able, so the current analysis reports on 148 participants.
Of these, 108 participated in CRC workshops and 40 in
NBS. Table 3 summarizes the demographic details of
these samples.
Workshop sizes ranged from six to 35 participants.
The mean ages of participants were 67 (range 53–88)
years for CRC workshops and 35 (27–48) years for
T1DM. Overall, participant groups were largely female
(72 %), white (76 %), and English speaking (73 %). The
average level of educational attainment was higher for
ON participants than NL. The majority of respondents
had not had personal experience of the condition in
question (75/80 (94 %) in the CRC workshops, 39/40
(98 %) in the T1DM workshops), while almost a third of
participants had a family member who had experience of
the condition in question (26/79 (33 %) in the CRC
workshops, 11/40 (28 %) in the T1DM workshops).
Tracker questions
After the first information set, the degree of support for
the provincial coverage for a DNA risk test differed
between the two groups (Fig. 2a and b). The CRC partici-
pants groups indicated a significantly higher level of initial
support (77 % “definite” support) compared to the T1DM
groups (30 %) (χ2 (4) = 22.297, p < 0.01, n = 100). These
differences persisted in the end-of-workshop data (CRC
70 %, T1DM 41 % “definite” support), although no longer
statistically significant. (χ2 (4) = 7.865, p = 0.10, n = 88).
The median scores showed no statistically significant
trend over the three rounds of the workshops for either
CRC or T1DM, whether examined by round 1 to round
3 (CRC, p = 0.15, T1DM, p =0.39), or round by round
(data not shown).
Of the 51 CRC participants for whom complete data
(all three rounds) were available, and irrespective of their
baseline response, 42 (82 %) did not change their attitude,
7 (14 %) became less positive and 2 (4 %) became more
positive. Of the 31 T1DM participants with complete data,
19 (61 %) did not change, 7 (23 %) became less positive,
and 5 (16 %) became more positive. Overall levels of
change were not statistically significant between the two
topic groups (p = 0.81), nor were changes between rounds
1 and 2 (p = 0.21) or rounds 2 and 3 (p = 0.27).
Figure 3a and b present the responses to the second
tracker attitude question, about the personal use of a gen-
omic risk profiling test. In the CRC groups, a clear major-
ity of participants (76 %) indicated a positive attitude
(“definitely yes”) to the idea of having a personal genomic
risk profiling test compared to 28 % in the T1DM groups
(χ2 (4) = 29.54, p < 0.01, n = 102). This support was main-
tained across the course of the workshop, but somewhat
lower than the question about public funding. Differences
between the groups remained so at the end of the work-
shop, with 59 % of participants in the CRC groups indicat-
ing “definitely yes” to the idea of having a personal
genomic risk profiling test compared to only 9 % in the
T1DM groups (χ2 (4) = 30.037, p < 0.01, n = 88).
For the CRC groups, comparison of median scores
showed a statistically significant downward trend over
the three rounds of the workshops (p = 0.02), with no
discernible statistically significant shift between individ-
ual rounds (data not shown). For the T1DM groups, a
statistically significant downward trend was also evident
Table 3 Responses to end of workshop questions
Item CRC n/N (%) TIDM n/N (%) P-value (Χ2)
DNA risk tests for condition generally acceptable 88/98 (90) 19/33 (58) <0.01
Not interested in finding out risk of condition 8/97 (8) 13/33 (39) <0.01
Concerned that high risk result would cause extra worry 46/97 (47) 28/33 (88) <0.01
Concerned that test result would cause problems with insurance 71/96 (74) 30/33 (91) 0.24
Concerned about who might have access to test results 68/97 (70) 29/33 (88) 0.34
Knowing risk of condition would help plan properly for future 75/82 (87) 20/33 (69) 0.07
Test results could be important for other family members 84/97 (92) 22/32 (61) <0.01
Percentage of respondents who Strongly agree or Agree, case study topic. % reported are valid percent based on responses. CRC Colorectal Cancer, T1DM Type 1
Diabetes Mellitus
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across the workshop as a whole, (p = 0.003), apparently
attributable to a major downward shift from round 2 to
3 (p = 0.003).
Of the 52 CRC participants for whom complete data
(all three rounds) were available, 38 (73 %) did not
change their attitude, 12 (23 %) became less positive
and 2 (4 %) became more positive. Of the 32 T1DM
participants with complete data, 10 (31 %) did not
change, 17 (53 %) became less positive, and 5 (16 %)

























































Round 1 Round 2 Round 3
Definitely Yes Maybe Yes Not Sure Maybe No Definitely No
a
b
Fig. 2 a Responses to tracker attitude question 1 (public funding): CRC workshop. Percentage of respondents over time for each category of
response to the question: “If DNA risk tests for colon cancer, do you think [Province] should pay for them?” b Responses to tracker attitude question 1
(public funding): T1DM workshop. Percentage of respondents over time for each category of response to the question: “If DNA risk tests for type 1
diabetes became available, do you think [Province] should pay for them?”
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not statistically significant between the two topic
groups (p = 0.06), nor were changes between rounds 1
and 2 (p = 0.955). However, differences were seen in the
level of change between rounds 2 and 3 across groups
(p = 0.03).
Other attitude data
In general, across the range of items, participants in
the CRC group indicated more positive responses than
those in the T1DM group (Table 2). In addition, partic-
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Definitely Yes Maybe yes Not sure Maybe no Definitely no
a
b
Fig. 3 a Responses to tracker attitude question 2 (personal decision): CRC workshop. Percentage of respondents over time for each category of
response to the question: “When you think about your own situation, would you want to have a DNA risk test for colon cancer?” b Responses to
tracker attitude question 2 (personal decision): T1DM workshop. Percentage of respondents over time for each category of response to the
question: “When you think about your child’s situation, would you want him or her to have a DNA risk test for T1DM?”
Nicholls et al. BMC Medical Genomics  (2016) 9:25 Page 8 of 13
respect to asking their doctor for the test if available
(84/95 (88 %) CRC groups, 12/30 (40 %) T1DM groups
indicating they would ask their doctor for the test if
available; p < 0.01), and were significantly more in-
clined to considering paying for the test (71/96 = 74 %
CRC groups; 13/30 = 43 % T1DM groups; p < 0.01).
Participants in the T1DM group were significantly
more concerned than the CRC group that a high risk
result would cause extra worry (88 % in the T1DM
workshops agreed to some degree, compared with
47 % in the CRC workshops, p < 0.01). Both groups
indicated concerns about third party access to results
and insurance implications.
Word valences
Figure 4 presents the results of the valence question,
where participants were invited to select as many words
as they liked from a set, to represent their feelings about
genomic risk profiling.
Comparing the specific words chosen (Fig. 4), there
were statistically significant differences between the
respondents in the two case study scenarios with re-
spect to the percentage of respondents endorsing the
terms “mixed feelings”, “worried”, “enthusiastic”, and
“optimistic”. More participants in the CRC sessions
indicated that they were “enthusiastic” or “optimistic”
than their T1DM counterparts, while participants in
the T1DM workshops were more “worried” or had
“mixed feelings” than those in the CRC workshops. No
participants indicated that they were “indifferent” or
“horrified”.
Discussion
In this study we explored public attitudes toward hypo-
thetical genomic profiling tests for two common disor-
ders, to inform thinking about future implementation
and evaluation exercises. The design of this study was
driven by two concerns about factors that might influ-
ence the validity of public engagement exercises relating
to hypothetical technologies. The first was that, ideally,
participants should be able to relate to the idea of the
new technology in order to engage meaningfully in
deliberation about it. We therefore matched workshop
topics to types of participants, so that the starting point
for the exercise was their own experiences: personally
familiar with CRC screening, or being the parent of a
very young child. We were open with participants about
why they were invited, and encouraged them to relate
the subject matter to their or their family’s own health
decision making. The second concern was that a facilitator
might unduly influence discussions by communicating his
or her personal values or attitudes. Our solution was to
develop standardized, objective, evidence-informed infor-
mation sets to form a core educational component to the
workshop, and to serve as a reminder to facilitators “in
the moment” of their need to maintain as unbiased a
stance as possible.
Our results showed distinct differences in reactions to
the two proposed uses of genomic profiling/participant
groups. Overall, participants in the CRC workshops were
more supportive of the availability of genomic profiling
as an adjunct to CRC screening than were participants
in the T1DM workshops for genomic profiling for deter-



















































T1DM (N=40) CRC (N=108)
Fig. 4 Attitudes of participants indicated by valence words. Responses to question: “Which of the following words best describe what you feel about
the developments arising from new discoveries in genetics? (Please circle as many words as apply).” T1DM= Type 1 Diabetes Mellitus, CRC = Colorectal
Cancer. * = statistically significant difference at P = 0.05 between topic groups
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group, a high level of definite support for publicly-
funded provision of the technology was attenuated only
slightly over the course of the workshop, while in the
T1DM group, there was an increase in definite support,
but this was always outweighed by responses in the
combined “maybe yes/no” and “unsure” categories. The
intention of this question – about support for govern-
ment funding for an intervention – was to encourage a
“third party” perspective and promote its evaluation in a
very general way; we used this to gauge how comfortable
participants felt with the idea of the technology, and to
cut through any ambivalence they might have about it in
their personal situation.
The responses to the question about having the test
personally/for a child revealed such ambivalence, and
the two groups showed different patterns. After the first
information set and deliberation period, the CRC partici-
pants were as definitively positive about the personal use
of genomic profiling as they were about its public avail-
ability. However, while always remaining the majority
response, the gradual reduction in the “definite” personal
acceptability of the test over the course of the workshop
was greater than that observed for the public availability
question; it was accompanied by an increase in the pro-
portion responding “not sure”. Like the CRC group, at
the first round, the T1DM group responded to the per-
sonal use question similarly to the public availability item,
with around 30 % of responses “definitely” in favour, and
two thirds falling across the “maybe yes/no” or “unsure”
categories. In the second round of questions, responses
shifted slightly from the “maybe yes” to “definitely yes”
categories, but by the final round, less than ten percent
were definitely in favour, with a very large shift into the
“not sure” group.
The end-of-workshop survey also showed differences
between the CRC and T1DM groups in their broader as-
sessments of genomic profiling in their two contexts.
Overall, around 90 % of the CRC respondents indicated
that genomic profiling as an adjunct to CRC screening
was an acceptable technology, they expressed an interest,
agreed that it would provide information useful to plan-
ning for their health, and of importance to their relatives.
T1DM respondents were also positive, but less so, with
rates of agreement on these areas around 60 %. While less
than half of the CRC participants indicated that a genomic
profiling test might generate anxiety, close to 90 % of
T1DM participants did.
Our findings of different responses across the questions
and groups suggest that context indeed matters, and that
participants weighed the general and personal utilities dif-
ferently, separating their own intention to use the technol-
ogy from general questions regarding the permissibility of
having the technology available to others who might wish
to use it.
Henneman et al. [53], for example, have noted that
while around two thirds of a sample of the Dutch public
indicated that genetic tests should be available to those
who want to use them, 57 % in 2002 and 45 % in 2010
also noted that they did not want to know what kind of
diseases they could get in the future. In a Finnish study,
Aro et al. [54] found that, while 90 % of respondents ac-
cepted that genetic testing should be available to those
who want to gather information about their genetic
health, less than two thirds would test their own child
for a predisposition for cardiovascular disease.
While the above studies did not address the differ-
ences between general acceptability and personal inter-
est, a recent systematic review of factors associated with
genetic testing decisions identified a number of disorder-
and test-related predictors of genetic testing uptake [55].
This noted that perceived control, perceived benefits,
and perceived barriers (such as cost or difficulty of test-
ing) were robust predictors of genetic test uptake. It
may, therefore, be that participants identified important
characteristics of either the disease or test that influ-
enced their decisions. Indeed, the noted difference with
respect to worry that could be brought about by results
may be indicative of differences. However, the explora-
tory nature of the study means that attribution of causal
factors for the differences is speculative and experimen-
tal designs are needed to further explore the role of
potential predictors of attitudes.
This study concerned attitudes towards the potential
use of hypothetical genomic profiling tests. We cannot
say with certainty what the uptake of such tests would be
in practice, and neither can we be sure that the differences
we observed were to do with the different participant
groups rather than the tests themselves. These differing
socio-demographics should be considered part of the test-
ing context, given that specific genetic tests are more rele-
vant and salient for specific population segments.
By definition, older people have decades’ more experi-
ence in making personal health decisions. While the spe-
cific context of decision-making for genomic technologies
may be new, we suggest that the greater experience of
making healthcare decisions could play a role in the
responses seen with older participants more confident in
personal assessments of benefit and risk than new parents.
Perhaps the differences we observed in their attitudes have
little to do with the purposes of the tests. However, these
two groups are indicative of the real decision makers were
these tests to become actually available, so the findings
may give a reasonably valid representation of differences
in how they would actually react. The information we pro-
vided during the workshop covered the kinds of issues
that would probably be expected for fully informed deci-
sion making in contexts. Even if people become more
confident and positive towards genetic information as they
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grow older, it makes no difference in practice: decision
making about a genetic profiling test on behalf of a child
could not wait until the parents are more experienced.
However, given the noted limitations, future studies might
wish to consider studies of gender, education, and cultural
influences and how these interact (or moderate) the effect
of attitudes for genomic interventions and how these may
vary by disease type.
The purpose of the study was to gain insights that
might be relevant for developing effective implementa-
tion strategies for genomic profiling approaches, should
they be shown to have potential utility. Taken at face
value, our results suggest that meaningful and effective
education is important to ensure genuinely informed de-
cision making. The task may be more straightforward
when the target population is more mature in its health
decision making experience, and when the genomic ap-
proach can be explained in relation to an existing, famil-
iar screening program, in which the preventability of the
condition (CRC) is emphasized in educational materials.
The issue of the utility of the genetic information seems to
be central to individuals’ evaluations of genomic profiling.
In a previous publication on this topic [21] in which we
reported the results of qualitative analyses, we discussed
how parental evaluations of the utility of genomic profil-
ing for T1DM risk were associated with perceptions of the
condition’s preventability. In the present study, the pur-
pose of risk prediction for T1DM was framed not as
prevention of the condition, but rather early identification
of symptoms that may prevent clinical manifestation of
severe outcomes such as keto-acidosis at diagnosis. The
realisation by participants that T1DM is not yet prevent-
able through behaviour changes was always accompanied
by a shift in the focus of discussion towards what might
be lost: normal family life and an unencumbered relation-
ship with their child.
Despite the differences between the topic groups, an
area of consistent concern between the groups was about
who would have access to genomic profiling test results,
and how the information would be used, particularly in
terms of insurance. While the evidence regarding the ac-
tual occurrence of genetic discrimination in insurance
may be equivocal [56], the perception seems to persist that
genetic testing may lead to discrimination by insurance
companies or employers. It seems that this may always
need to be borne in mind when developing policy and
implementing genomic technologies in healthcare. Con-
cern over insurance was not a high profile topic in Canada
at the time of this study, but it seems nevertheless to have
a particular and persistent salience.
Our findings add to a growing literature regarding atti-
tudes to tests for genetic susceptibility to serious com-
plex disorders. Leventhal et al. [4] examined interest in
SNP-based genomic profiling in adults, and found higher
interest in learning about cancer-associated SNPs than
for diabetes-associated SNPs. Anderson et al. [34] found
similar results in participants enrolled in the Family
Colorectal Cancer Risk Awareness and Risk Education
Project (Family CARE) project, with 74 % of partici-
pants indicating at least some interest in predictive
SNP testing for colorectal cancer [57]. Likewise,
Veldwijk et al. [58] found strong support for genetic
screening for CRC within the target population in
the Netherlands. However, in contrast to the distinct
hesitancy observed in our study, Tarini et al. [59]
found parental reactions to predictive genetic testing of
their children split evenly between interest, equivoca-
tion, and disinterest for a range of hypothetical disease
scenarios.
Our results must be considered within the limitations
of the study. First, this was a self-selected sample and so
the opinions expressed may not be reflective of the gen-
eral population. Indeed, perhaps we attracted individuals
with strong positive or negative views towards genomic
tests. This may be the case for the CRC groups, but does
not seem to apply to the T1DM participants. From our
data, it was impossible to examine the mechanism by
which the workshop process shifted individual attitudes
on the topic. We did not capture data to assess the im-
pact of the information sets on immediate knowledge or
understanding. While we developed the information sets
to bring participants “up to speed” on multiple aspects
of the topics, we cannot separate their effect (if any)
from the deliberative discussions or even just giving
participants some dedicated space and time to reflect
on the subject in an undirected way. We do suggest,
however, that single, cross-sectional surveys cannot
be relied on to capture valid attitude data about the
acceptability of hypothetical genomic technologies in
personal health contexts. We must assume that per-
sonal evaluations of utility may evolve depending on
personal experience, information provided, the extent
of deliberation, and/or the opportunity for individual
reflection.
Conclusions
The findings of this study suggest that members of the
target populations for potential genomic profiling tests
(designed for screening or risk prediction purposes) can
engage in meaningful deliberation about their general
acceptability and personal utility. Evaluations of whether
a test would be personally useful may depend on the ex-
perience of the participants in personal health decision
making, the purpose of the test, and the availability of
interventions to reduce disease risk. On the face of it,
genomic profiling for CRC risk, as an adjunct to current
population screening approaches, seems a highly accept-
able intervention; the focus of implementation efforts
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might be on logistics (how it fits with the screening
process), and ensuring that it is not misunderstood as a
cancer detection test in its own right. In contrast, the
uptake of a T1DM genomic susceptibility test (should
one be developed) would be dependent on individual
assessments of a wider range of benefits and harms,
and would require a shared decision making model.
This could involve the development of effective parental
decision aids, but would also likely demand interven-
tions to ensure that providers themselves evaluated
such technology positively, and were capable of pro-
viding appropriate support to parents, in their decision
making.
The methodology reported here may offer preliminary
insights into how information provision may be combined
with semi-structured deliberation to generate attitude data
that are perhaps more valid than one-off cross-sectional
survey approaches. Much more needs to be done to
evaluate the validity of such an approach, in terms of the
stability of attitude data and association with actual health
decisions.
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